Immune checkpoint inhibitor-associated inflammatory arthritis

Carrie Ye, David F. L. Liew, Shahin Jamal
Nature Reviews Rheumatology · Springer Nature · 2026-11-06 · DOI: 10.1038/s41584-026-01452-9

Аннотация

Nature Reviews Rheumatology, Published online: 06 November 2026; doi:10.1038/s41584-026-01452-9 Immune checkpoint inhibitor-associated inflammatory arthritis is the most common rheumatic immune-related adverse event. In this Review, the authors discuss current insights into the pathogenesis, clinical presentations and management of immune checkpoint inhibitor-associated inflammatory arthritis, underscoring its distinct biology and therapeutic considerations.

Читать у издателя →

Похожие статьи